Calvin W. Roberts - 11 Jul 2023 Form 4 Insider Report for IVERIC bio, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 11 Jul 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Jul 2023, 13:59:44 UTC
Prior SEC filing: 19 May 2023
Source filing: View source filing
Reporting owner signature: /s/ Todd D.C. Anderman, as Attorney-in-Fact for Calvin W. Roberts

Key filing fact

Calvin W. Roberts filed Form 4 for IVERIC bio, Inc. on 13 Jul 2023.

Key facts

This page summarizes Calvin W. Roberts's Form 4 filing for IVERIC bio, Inc..
7 reported transactions and 6 derivative rows are listed below.
Accepted by SEC: 13 Jul 2023, 13:59.

Change

Previous filing in this sequence was filed on 19 May 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ISEE transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -47,088
Change %: -100%
Price
Shares after: 0
Date: 11 Jul 2023
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ISEE transaction Derivative

Restricted Stock Units

Disposed to Issuer

Transaction value
Shares: -7,500
Change %: -100%
Price
Shares after: 0
Date: 11 Jul 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,500
Exercise price
Footnotes: F2, F3

ISEE transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -32,000
Change %: -100%
Price
Shares after: 0
Date: 11 Jul 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 32,000
Exercise price: $1.20
Footnotes: F4

ISEE transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -16,000
Change %: -100%
Price
Shares after: 0
Date: 11 Jul 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,000
Exercise price: $1.39
Footnotes: F4

ISEE transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -16,000
Change %: -100%
Price
Shares after: 0
Date: 11 Jul 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,000
Exercise price: $4.14
Footnotes: F4

ISEE transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -15,500
Change %: -100%
Price
Shares after: 0
Date: 11 Jul 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,500
Exercise price: $6.82
Footnotes: F4

ISEE transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -23,186
Change %: -100%
Price
Shares after: 0
Date: 11 Jul 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 23,186
Exercise price: $9.94
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Calvin W. Roberts is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 4 footnotes

Footnote F1

On July 11, 2023, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated April 28, 2023, by and among IVERIC bio, Inc. ("IVERIC"), Astellas US Holding, Inc., Berry Merger Sub, Inc. ("Merger Sub") and, solely as provided by Section 8.10(b) of the Merger Agreement, Astellas Pharma Inc. ("Astellas"), Merger Sub merged with and into IVERIC, with IVERIC surviving the merger and becoming an indirect wholly owned subsidiary of Astellas (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of IVERIC common stock ("Common Stock") reported in this Form 4 was automatically cancelled and was converted into the right to receive $40.00 in cash, without interest and less any applicable withholding taxes.

Footnote F2

Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU.

Footnote F3

Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU.

Footnote F4

Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof.